Difference between revisions of "PARP inhibitors"

From Libre Pathology
Jump to navigation Jump to search
 
Line 11: Line 11:
*Olaparib (Lynparza).<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref>
*Olaparib (Lynparza).<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref>
*Rucaparib (Rubraca).
*Rucaparib (Rubraca).
*Niraparib (Zejula).
*Niraparib (Zejula).<ref>URL: [https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors]. Accessed on: 2024 June 10.</ref>


==See also==
==See also==

Latest revision as of 18:28, 10 June 2024

PARP inhibitors are a class of cancer drugs.

PARP is an abbreviation for poly-ADP ribose polymerase.

Use

  • Prostate cancer.
  • Breast cancer.
  • Ovarian cancer.

Drugs

  • Olaparib (Lynparza).[1]
  • Rucaparib (Rubraca).
  • Niraparib (Zejula).[2]

See also

References